After an official request from Edwards Lifesciences, CMS is rethinking its coverage policy for the use of TAVR to treat asymptomatic severe aortic stenosis. The agency is accepting public comments on this topic until Jan. 14. After an official request from Edwards Lifesciences, CMS is rethinking its coverage policy for the use of TAVR to treat asymptomatic severe aortic stenosis. The agency is accepting public comments on this topic until Jan. 14. | | |
|
On Dec. 11, the Alaskan cardiologist was captured as part of a months-long investigation and charged with 10 counts of possessing child sexual abuse materials. The fire at his home occurred two days later. On Dec. 11, the Alaskan cardiologist was captured as part of a months-long investigation and charged with 10 counts of possessing child sexual abuse materials. The fire at his home occurred two days later. | | |
|
The new guidance, published in JACC, focuses on three classes of commonly used anticancer therapies. The new guidance, published in JACC, focuses on three classes of commonly used anticancer therapies. | | |
|
A fifth-generation TAVR valve from Edwards Lifesciences was associated with improved outcomes compared to the device's predecessors in a new real-world analysis out of Cedars Sinai. A fifth-generation TAVR valve from Edwards Lifesciences was associated with improved outcomes compared to the device's predecessors in a new real-world analysis out of Cedars Sinai. | | |
|
|
Three out of four TTEs are being ordered by clinicians who are not cardiologists. Could this be having a negative impact on patient care? Three out of four TTEs are being ordered by clinicians who are not cardiologists. Could this be having a negative impact on patient care? | | |
|
Massachusetts-based SpectraWAVE has gained considerable momentum in recent years, planting its flag in some of cardiology’s biggest trends. The company was co-founded by cardiologists and has already secured multiple FDA clearances. Massachusetts-based SpectraWAVE has gained considerable momentum in recent years, planting its flag in some of cardiology’s biggest trends. The company was co-founded by cardiologists and has already secured multiple FDA clearances. | | |
|
Milestone Pharmaceuticals will be selling etripamil under the brand name Cardamyst. It is expected to hit the U.S. market in early 2026. Milestone Pharmaceuticals will be selling etripamil under the brand name Cardamyst. It is expected to hit the U.S. market in early 2026. | | |
|
The new device uses an advanced algorithm to regulate aspiration and conserve blood. Ajit Rao, MD, a vascular surgeon with The Mount Sinai Hospital, performed the historic procedure. The new device uses an advanced algorithm to regulate aspiration and conserve blood. Ajit Rao, MD, a vascular surgeon with The Mount Sinai Hospital, performed the historic procedure. | | |
|
|
Abdominal obesity, the phenomenon commonly known as “beer belly," may be associated with significant risks, including heart failure. Researchers urged cardiologists and radiologists alike to keep these findings in mind going forward. Abdominal obesity, the phenomenon commonly known as “beer belly," may be associated with significant risks, including heart failure. Researchers urged cardiologists and radiologists alike to keep these findings in mind going forward. | | |
|
The new software, announced at RSNA 2025 in Chicago, was built to evaluate CCTA images for signs of coronary artery disease and improve cath lab efficiency. The new software, announced at RSNA 2025 in Chicago, was built to evaluate CCTA images for signs of coronary artery disease and improve cath lab efficiency. | | |
|
Hospitals could be turning away high-risk heart patients to help their TAVR programs receive a higher ranking, according to new research published in JACC: Cardiovascular Interventions. Hospitals could be turning away high-risk heart patients to help their TAVR programs receive a higher ranking, according to new research published in JACC: Cardiovascular Interventions. | | |
|
|
The most funded categories across the specialty included medical devices ($3.2B), AI software ($2.5B), and biotechnology ($2.1B). The most funded categories across the specialty included medical devices ($3.2B), AI software ($2.5B), and biotechnology ($2.1B). | | |
|
The director of the National Institutes of Health and his principal deputy are touting their success at ‘curing’ the agency of its self-inflicted DEI disability. The director of the National Institutes of Health and his principal deputy are touting their success at ‘curing’ the agency of its self-inflicted DEI disability. | | |
|
